IPN Share Price

Open 91.59 Change Price %
High 91.72 1 Day -0.16 -0.17
Low 90.96 1 Week 1.21 1.34
Close 91.48 1 Month 8.51 10.26
Volume 44738 1 Year 43.33 89.99
52 Week High 91.76
52 Week Low 47.60
IPN Important Levels
Resistance 2 92.18
Resistance 1 91.89
Pivot 91.39
Support 1 91.07
Support 2 90.78
EPA France Most Active Stocks
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
BRS 12.00 0.00%
BRS 12.00 0.00%
More..
EPA France Top Gainers Stocks
MLPHW 0.85 30.77%
VRNL 0.75 29.31%
MLNOV 7.64 29.05%
ALALO 0.05 25.00%
APAM 33.78 15.72%
APAM 33.78 15.72%
MLLOI 3.80 15.15%
DEXB 17.47 13.89%
DEXB 17.47 13.89%
MT 4.53 12.97%
More..
EPA France Top Losers Stocks
MLGEO 0.05 -16.67%
MLEVE 0.08 -11.11%
ITL 15.04 -11.06%
ITL 15.04 -11.06%
LAF 20.61 -6.74%
BAIN 32.66 -6.55%
ALDIE 1.30 -6.47%
ALENT 0.76 -5.00%
DPT 0.19 -5.00%
GUI 1.48 -4.52%
More..

Ipsen (EPA: IPN)

IPN Technical Analysis 5
As on 24th Mar 2017 IPN Share Price closed @ 91.48 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 64.21 & Strong Buy for SHORT-TERM with Stoploss of 79.50 we also expect STOCK to react on Following IMPORTANT LEVELS.
IPN Target for March
1st Target up-side 90.52
2nd Target up-side 95.23
3rd Target up-side 99.94
1st Target down-side 77.08
2nd Target down-side 72.37
3rd Target down-side 67.66
IPN Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.ipsen.com
IPN Address
IPN
65, quai Georges Gorse
Cedex
Boulogne-Billancourt, 92650
France
Phone: 33 1 58 33 50 00
Fax: 33 1 58 33 50 01
Interactive Technical Analysis Chart Ipsen ( IPN EPA France )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Ipsen
IPN Business Profile
Ipsen S.A. operates as a pharmaceutical company worldwide. It offers drugs in the areas of uro-oncology, endocrinology, neurology, gastroenterology, cardiovascular, and cognitive disorders. The company’s products include Decapeptyl, a peptide formulation for injection in the treatment of advanced prostate cancer; Hexvix that is used to enhance detection of bladder cancer; and Somatuline and Somatuline Autogel, which are used in the treatment of acromegaly and neuroendocrine tumours. Ipsen S.A. also offers NutropinAq, a liquid formulation used in the treatment of growth failure in children and growth hormone deficiency in adults; Increlex, a formulation used for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor 1 deficiency; and Dysport, a botulinum neurotoxin type A complex used to treat spasticity of upper limbs following a stroke, as well as the spasticity of other muscles. In addition, it provides Smecta, a natural clay-based drug used in the treatment of chronic and acute diarrhea; Forlax, a drug based on a linear polyethylene glycol polymer used in the treatment of constipation; and Tanakan that is used in the treatment of age-related cognitive disorders. Further, the company offers Nisis and Nisisco oral formulations containing valsartan used in the treatment of hypertension; and Adenuric for the treatment of gout. Additionally, it is developing products in the areas of neurology, endocrinology, and uro-oncology, including BN82451, Tasquinimod, Somatuline Autogel, Dysport, Dysport Next Generation, and Decapeptyl. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.